Autolus Therapeutics Logo
US05280R1005
A2JNZJ
AUTL

Autolus Therapeutics

Loading quotes...

Forecast

The analysts' average price target is €8.09 (+742.71%). The median is €7.29 (+659.38%).

Buy
  11
Hold
  3
Sell
  0

Discussions in the community

There is no discussion about this asset yet.

Start discussion

  • FDA grants Autolus RMAT designation for lupus therapy Obe-cel

    The US FDA has granted Autolus’ cell therapy Obecabtagene Autoleucel (Obe-cel) RMAT designation for the treatment of systemic lupus erythematosus and lupus nephritis to accelerate development and review. The designation is based on data from the phase 1b CARLYSLE study. The approval‑enabling phase 2 study LUMINA is currently recruiting in five countries; Autolus expects study data in 2028 and has submitted a data update for the ACR annual meeting in Q4 2026. » More on de.investing.com


  • Autolus Therapeutics grants stock options and RSUs to 13 new employees

    Autolus Therapeutics granted inducement awards under its 2025 Inducement Plan comprising options to purchase 25,420 American Depositary Shares and 87,530 restricted stock units to 13 new hires. Awards have a grant date of June 24, 2026; options carry a $1.66 exercise price, a ten-year term and vest over four years, while RSUs vest in four equal annual installments. The grants were made in accordance with Nasdaq Listing Rule 5635(c)(4). » More on finance.yahoo.com


  • Autolus Therapeutics publishes UK annual report and schedules annual general meeting

    Autolus Therapeutics has published its UK annual report for the fiscal year ended 31 December 2025 and has convened the annual general meeting for 29 June 2026. The report, the notice of the AGM and a proxy form were sent to ordinary shareholders on 5 June; Citibank, as depositary bank, began sending notifications to ADS holders around 8 June. ADS holders who were registered as shareholders on 27 May can instruct the depositary bank to exercise their voting rights, although exercising those rights may be delayed or not occur in time due to practical and legal constraints. » More on de.investing.com


  • Autolus Therapeutics changes auditor, appoints Ernst & Young LLP (US) for 2026

    Autolus Therapeutics has dismissed Ernst & Young LLP (UK) and, with immediate effect, appointed Ernst & Young LLP (US) as auditor for the year ending 31 December 2026. There were no disagreements with Ernst & Young LLP (UK) and no audit qualifications in the financial statements for 2024 and 2025. The company notes that its internal control over financial reporting was recently not effective due to material weaknesses. » More on de.investing.com


  • Mizuho cuts Autolus Therapeutics price target to $10, maintains outperform

    Mizuho lowered its price target on Autolus Therapeutics to $10 from $12 and kept an Outperform rating after updating models across its small-cap biotech coverage following fourth-quarter results. Autolus reported Q4 EPS of $(0.34) vs $(0.43) consensus and revenue of $24.29 million vs $23.29 million consensus. CEO Christian Itin highlighted a strong first year of U.S. launch for AUCATZYL, citing good commercial execution and real‑world data showing clinical activity with low rates of high‑grade CRS and ICANS. » More on finance.yahoo.com

Financials

In the last quarter, Autolus Therapeutics had revenue of €36.41M and net profit of -€48.64M
(EUR) September 2026
YoY
Revenue 36.41M 101.59%
Gross profit 20.58M 424.22%
Net profit -48.64M 27.86%
EBITDA -36.24M 34.25%

Fundamentals

Metric Value
Market capitalization
€283.88M
Number of shares
266.16M
52-week high/low
€2.35 - €1.02
Dividends No
Beta
2.35
P/E ratio
-1.21
PEG ratio
0.06
P/B ratio
11.37
P/S ratio
2.27

Company profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma. It also focuses on developing AUTO5, a hematological product candidate, which is in preclinical development. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.

Name
Autolus Therapeutics
CEO
Christian Martin Itin
Headquarters London, gl
United Kingdom
Website
Sector
Health Care
Industry
Biotechnology
IPO
06/22/2018
Employees 752

Ticker symbols

Exchange Symbol
NASDAQ
AUTL
Frankfurt
6A3A.F
DĂĽsseldorf
6A3A.DU
MĂĽnchen
6A3A.MU
🍪

Parqet  uses cookies. Learn more